Development of a porcine acellular bladder matrix for tissue-engineered bladder reconstruction.


Journal

Pediatric surgery international
ISSN: 1437-9813
Titre abrégé: Pediatr Surg Int
Pays: Germany
ID NLM: 8609169

Informations de publication

Date de publication:
May 2022
Historique:
accepted: 02 02 2022
pubmed: 23 3 2022
medline: 8 4 2022
entrez: 22 3 2022
Statut: ppublish

Résumé

Enterocystoplasty is adopted for patients requiring bladder augmentation, but significant long-term complications highlight need for alternatives. We established a protocol for creating a natural-derived bladder extracellular matrix (BEM) for developing tissue-engineered bladder, and investigated its structural and functional characteristics. Porcine bladders were de-cellularised with a dynamic detergent-enzymatic treatment using peristaltic infusion. Samples and fresh controls were evaluated using histological staining, ultrastructure (electron microscopy), collagen, glycosaminoglycans and DNA quantification and biomechanical testing. Compliance and angiogenic properties (Chicken chorioallantoic membrane [CAM] assay) were evaluated. T test compared stiffness and glycosaminoglycans, collagen and DNA quantity. p value of < 0.05 was regarded as significant. Histological evaluation demonstrated absence of cells with preservation of tissue matrix architecture (collagen and elastin). DNA was 0.01 μg/mg, significantly reduced compared to fresh tissue 0.13 μg/mg (p < 0.01). BEM had increased tensile strength (0.259 ± 0.022 vs 0.116 ± 0.006, respectively, p < 0.0001) and stiffness (0.00075 ± 0.00016 vs 0.00726 ± 0.00216, p = 0.011). CAM assay showed significantly increased number of convergent allantoic vessels after 6 days compared to day 1 (p < 0.01). Urodynamic studies showed that BEM maintains or increases capacity and compliance. Dynamic detergent-enzymatic treatment produces a BEM which retains structural characteristics, increases strength and stiffness and is more compliant than native tissue. Furthermore, BEM shows angiogenic potential. These data suggest the use of BEM for development of tissue-engineered bladder for patients requiring bladder augmentation.

Identifiants

pubmed: 35316841
doi: 10.1007/s00383-022-05094-2
pii: 10.1007/s00383-022-05094-2
pmc: PMC8983501
doi:

Substances chimiques

Collagen 9007-34-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

665-677

Subventions

Organisme : Medical Research Council
ID : MR/L013347/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N028414/1
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Ther Adv Urol. 2009 Apr;1(1):5-11
pubmed: 21789049
BJU Int. 2011 Oct;108(7):1046-65
pubmed: 21895928
Acta Biomater. 2019 Feb;85:131-141
pubmed: 30553012
Pediatr Surg Int. 2013 Jan;29(1):87-95
pubmed: 23124129
PLoS One. 2013;8(2):e56237
pubmed: 23409160
J Mech Behav Biomed Mater. 2011 Apr;4(3):375-82
pubmed: 21316625
Acta Biomater. 2010 Mar;6(3):1158-66
pubmed: 19733702
Eur Urol. 2011 Mar;59(3):447-54
pubmed: 21195539
J Pediatr Urol. 2008 Oct;4(5):381-5; discussion 386
pubmed: 18653384
BJU Int. 2004 Mar;93(4):609-16
pubmed: 15008741
Int J Urol. 2007 Aug;14(8):673-8
pubmed: 17681053
Tissue Eng Part C Methods. 2010 Oct;16(5):1201-11
pubmed: 20170425
Expert Opin Biol Ther. 2018 May;18(5):525-544
pubmed: 29436241
J Urol. 2014 May;191(5):1389-95
pubmed: 24184366
Biomaterials. 2007 Feb;28(6):1061-70
pubmed: 17092557
Pediatr Surg Int. 2012 Apr;28(4):421-8
pubmed: 22350082
Biomaterials. 2012 Apr;33(12):3401-10
pubmed: 22305104
J Urol. 2020 Feb;203(2):413-419
pubmed: 31518199
World J Urol. 2020 Sep;38(9):2279-2288
pubmed: 31712957
Tissue Eng Part A. 2018 Jan;24(1-2):11-20
pubmed: 28322621
BJU Int. 2014 Sep;114(3):447-57
pubmed: 25302355
Tissue Eng. 2004 Jan-Feb;10(1-2):181-7
pubmed: 15009944
Biomaterials. 2009 Jan;30(2):266-75
pubmed: 18926570
Methods. 2009 Feb;47(2):109-15
pubmed: 18952175
J Urol. 2002 Jan;167(1):84-8
pubmed: 11743281
Eur J Pediatr Surg. 2014 Jun;24(3):227-36
pubmed: 24918400
J Pediatr Urol. 2015 Oct;11(5):260.e1-6
pubmed: 26022502
Nat Med. 2008 Feb;14(2):213-21
pubmed: 18193059
J Pediatr Urol. 2013 Dec;9(6 Pt A):878-83
pubmed: 23332207
J Tissue Eng Regen Med. 2010 Feb;4(2):123-30
pubmed: 19842107
J Urol. 2012 Aug;188(2):464-9
pubmed: 22704106
Lancet. 2012 Sep 15;380(9846):994-1000
pubmed: 22841419
Biomaterials. 2013 Sep;34(28):6638-48
pubmed: 23727263
J Tissue Eng. 2021 Feb 6;12:2041731420986796
pubmed: 33613958
Int Rev Cell Mol Biol. 2008;270:181-224
pubmed: 19081537
Polymers (Basel). 2020 Dec 16;12(12):
pubmed: 33339345
Acta Biomater. 2009 Jan;5(1):1-13
pubmed: 18938117
BJU Int. 2006 Nov;98(5):1100-5
pubmed: 17034611
Tissue Cell. 2020 Dec;67:101443
pubmed: 32998076
Lancet. 2006 Apr 15;367(9518):1241-6
pubmed: 16631879
Surgeon. 2018 Feb;16(1):55-65
pubmed: 28811169
Nat Biotechnol. 1999 Feb;17(2):149-55
pubmed: 10052350
J Urol. 2010 Jun;183(6):2432-9
pubmed: 20403614

Auteurs

Massimo Garriboli (M)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
Department of Nephro-Urology, Evelina London Children's Hospital, Guys and St. Thomas NHS Foundation Trust, London, UK.

Koichi Deguchi (K)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.
Department of Pediatric Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Giorgia Totonelli (G)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Fanourios Georgiades (F)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Luca Urbani (L)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Marco Ghionzoli (M)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Alan J Burns (AJ)

Neural Development Unit, Institute of Child Health, University College London, 30 Guilford Street, London, UK.

Neil J Sebire (NJ)

Department of Histopathology, Institute of Child Health and Great Ormond Street Hospital, University College London, London, UK.

Mark Turmaine (M)

Division of Bioscience, University College London, London, UK.

Simon Eaton (S)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK.

Paolo De Coppi (P)

Stem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. p.decoppi@ucl.ac.uk.
Paediatric Surgery Department, Great Ormond Street Hospital, London, UK. p.decoppi@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH